Characteristics and Outcome of AKT1 ^E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.

ABSTRACT: AKT inhibitors have promising activity in AKT1 ^E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinical outcomes of patients with matched AKT1 ^E17K-mutant (n = 153) and AKT1-wild-type (n = 302) metastatic breast cancer. AKT1-mutant cases had similar adjusted overall survival (OS) compared with AKT1-wild-type controls (median OS, 24.1 vs. 29.9, respectively; P = 0.98). AKT1-mutant cases enjoyed longer durations on mTOR inhibitor therapy, an observation previously unrecognized in pivotal clinic

SUBMITTER: Smyth LM 

PROVIDER: S-EPMC7125034 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature